Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluentialCBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Zhang, Y., & Reinberg, D. (2001) · Genes & Development · doi:10.1101/gad.927301 · Cited by 1,530
Vascular Endothelial Growth Factor
Ferrara, N. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179663 · Cited by 1,283
Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation
Chen, L.-F., Fischle, W., Verdin, E., & Greene, W. C. (2001) · Science · doi:10.1126/science.1062374 · Cited by 1,222
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
Rountree, M. R., Bachman, K. E., & Baylin, S. B. (2000) · Nature Genetics · doi:10.1038/77023 · Cited by 1,052
Green, D. R. (2000) · Cell · doi:10.1016/s0092-8674(00)00003-9 · Cited by 1,008
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001) · Nature · doi:10.1038/35051606 · Cited by 966 · cited 1×
“cgi?l=841">caspase-8 , have been correlated with cancer onset and progressio”
BackgroundRobertson, K. D., Ait-Si-Ali, S., Yokochi, T., Wade, P. A., Jones, P. L., & Wolffe, A. P. (2000) · Nature Genetics · doi:10.1038/77124 · Cited by 942
MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex
Ng, H.-H., Zhang, Y., Hendrich, B., Johnson, C. A., Turner, B. M., Erdjument-Bromage, H., Tempst, P., Reinberg, D., & Bird, A. (1999) · Nature Genetics · doi:10.1038/12659 · Cited by 936
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000) · Nature · doi:10.1038/35042612 · Cited by 818
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
Esteller, M., & Herman, J. G. (2002) · The Journal of Pathology · doi:10.1002/path.1024 · Cited by 743 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
BackgroundDNA methylation, methyltransferases, and cancer
Robertson, K. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204341 · Cited by 736 · cited 3×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731 · cited 1×
“cgi?l=7422"> VEGF ) and suppress angiogenesis, both in vitro and in vivo”
BackgroundAshburner, B. P., Westerheide, S. D., & Baldwin, A. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.7065-7077.2001 · Cited by 730
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Histone acetylases and deacetylases in cell proliferation
Kouzarides, T. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80006-9 · Cited by 601 · cited 1×
“In addition, genetic abnormalities that result in the improper targeting of HATs or HDACs to certain loci, functional inactivation of HATs, overexpression of HDACs or epigenetic changes due to DNA hyper- and hypomethylation, can mediate tumour onset and progressio”
BackgroundMutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587 · cited 1×
“gov/cancer_information/cancer_type/breast/">breast cancers , and glioblastoma”
The Human Histone Deacetylase Family
Gray, S. G., & Ekström, T. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5080 · Cited by 546 · cited 1×
“So far, 17 human genes that encode proven or putative HDACs have been identified, which can be classified into three distinct familie”
BackgroundHistone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502 · cited 1×
“Treatment of a patient with relapsed and RA-resistant APL (expressing PML – RARα ) with a combination of phenylbutyrate and RA resulted in complete clinical and cytogenetic remission of disease for six month”
BackgroundUEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 488 · cited 1×
“Analysis of the cell-cycle profiles of tumour cells that have been treated with HDAC inhibitors indicates that the cells often arrest in G1, but sometimes accumulate in what seems to be the G2 phase of the cycl”
BackgroundSelf-citationBCoR, a novel corepressor involved in BCL-6 repression
Huynh, K. D., Fischle, W., Verdin, E., & Bardwell, V. J. (2000) · Genes & Development · doi:10.1101/gad.14.14.1810 · Cited by 477
Dnmt3a binds deacetylases and is recruited by a sequence‐specific repressor to silence transcription
Fuks, F., Burgers, W. A., Godin, N., Kasai, M., & Kouzarides, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.10.2536 · Cited by 473
Vigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Mariadason, J. M., Corner, G. A., & Augenlicht, L. H. (2000) · PubMed · Cited by 415
Control of muscle development by dueling HATs and HDACs
McKinsey, T. A., Zhang, C. L., & Olson, E. N. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00224-0 · Cited by 414 · cited 1×
“, and the role of class II HDACs — including HDAC4 — in cellular differentiatio”
BackgroundFurumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412 · cited 1×
“Structure– function analyses of various CHAP derivatives have identified reversible compounds that can induce gene expression at nanomolar concentration”
BackgroundThe retinoblastoma gene family in differentiation and development
Lipinski, M. M., & Jacks, T. (1999) · Oncogene · doi:10.1038/sj.onc.1203244 · Cited by 405
Conjunction dysfunction: CBP/p300 in human disease
Giles, R. H., Peters, D. J. M., & Breuning, M. H. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01438-3 · Cited by 403
Münster, P. N., Troso-Sandoval, T. A., Rosen, N. X., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2001) · PubMed · Cited by 402
Histone acetyltransferases: function, structure, and catalysis
Marmorstein, R., & Roth, S. Y. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00173-8 · Cited by 401 · cited 1×
“Acetylation of the e-NH 2 group on lysine residues within histone tails correlates with nucleosome remodelling and transcriptional activatio”
BackgroundHistone Deacetylase 1 Can Repress Transcription by Binding to Sp1
Doetzlhofer, A., Rotheneder, H., Lagger, G., Koranda, M., Kurtev, V., Brosch, G., Wintersberger, E., & Seiser, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5504 · Cited by 398
DNA methylation, chromatin inheritance, and cancer
Rountree, M. R., Bachman, K. E., Herman, J. G., & Baylin, S. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204339 · Cited by 384
Functional significance of histone deacetylase diversity
Khochbin, S., Verdel, A., Lemercier, C., & Seigneurin-Berny, D. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00174-x · Cited by 366 · cited 1×
“Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13).”
BackgroundCoull, J. J., Romerio, F., Sun, J.-M., Volker, J. L., Galvin, K. M., Davie, J. R., Shi, Y., Hansen, U., & Margolis, D. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.15.6790-6799.2000 · Cited by 346
25 years after the nucleosome model: chromatin modifications
Wu, J. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01718-7 · Cited by 342 · cited 1×
“All of the human genome is packaged into chromatin, which is a dynamic macromolecular complex that consists of DNA, histones and non-histone protein”
BackgroundBRCA1 interacts with components of the histone deacetylase complex
Yarden, R. I., & Brody, L. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4983 · Cited by 330
He, L.-Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M., & Pandolfi, P. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11537 · Cited by 303 · cited 1×
“HDAC inhibitors can synergize with RA to induce the differentiation of RA- and chemotherapy-resistant PLZF – RARα -expressing APL cells both in vitro and in vivo”
BackgroundActivation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors
Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290
Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 284
Sequence-specific DNA recognition by polyamides
Dervan, P. B., & Bürli, R. W. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00027-7 · Cited by 283 · cited 1×
“Chimeric proteins that contain HAT or HDAC recruitment domains fused to hairpin polyamide”
Backgroundp300 gene alterations in colorectal and gastric carcinomas.
Muraoka, M., Konishi, M., Kikuchi‐Yanoshita, R., Tanaka, K., Shitara, N., Chong, J., Iwama∥, T., & Miyaki, M. (1996) · PubMed · Cited by 282
p300/CBP/p53 interaction and regulation of the p53 response
Grossman, S. R. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02226.x · Cited by 263
Histone deacetylase as a therapeutic target
Krämer, O. H., Göttlicher, M., & Heinzel, T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00438-6 · Cited by 257
UEDA, H., MANDA, T., MATSUMOTO, S., MUKUMOTO, S., NISHIGAKI, F., KAWAMURA, I., & SHIMOMURA, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.315 · Cited by 257
Qiu, L., Burgess, A., Fairlie, D. P., Leonard, H., Parsons, P. G., & Gabrielli, B. G. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.6.2069 · Cited by 249 · cited 1×
“Analysis of the cell-cycle profiles of tumour cells that have been treated with HDAC inhibitors indicates that the cells often arrest in G1, but sometimes accumulate in what seems to be the G2 phase of the cycl”
BackgroundDNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Zhu, W., Lakshmanan, R. R., Beal, M. D., & Otterson, G. A. (2001) · PubMed · Cited by 246
Coordinating cell proliferation and differentiation
Zhu, L., & Skoultchi, A. I. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00162-3 · Cited by 246 · cited 1×
“The coordinated activities of cyclins, CDKs, CDK inhibitors and RB family members are required for differentiation in many system”
BackgroundLiu, P.-Q., Rebar, E. J., Zhang, L., Liu, Q., Jamieson, A. C., Liang, Y., Qi, H., Li, P.-X., Chen, B., Mendel, M. C., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011172200 · Cited by 239
Gilbert, J., Baker, S. D., Bowling, M. K., Grochow, L. B., Figg, W. D., Zabelina, Y., Donehower, R. C., & Carducci, M. A. (2001) · PubMed · Cited by 227
Class I Histone Deacetylases Sequentially Interact with MyoD and pRb during Skeletal Myogenesis
Puri, P. L., Iezzi, S., Stiegler, P., Chen, T.-T., Schiltz, R. L., Muscat, G. E. O., Giordano, A., Kedes, L., Wang, J. Y. J., & Sartorelli, V. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00373-2 · Cited by 224
Kwon, S. H., Ahn, S. H., Kim, Y. K., Bae, G.-U., Yoon, J. W., Hong, S., Lee, H. Y., Lee, Y.-W., Lee, H.-W., & Han, J.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106699200 · Cited by 215 · cited 1×
“However, most tumour cells that do not arrest in G1 after HDAC-inhibitor treatment replicate their DNA, and subsequently undergo apoptosi”
BackgroundFusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13)
Panagopoulos, I. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.4.395 · Cited by 214 · cited 1×
“cgi?l=10499">TIF2 (transcriptional intermediary factor 2), have also been associated with AM”
BackgroundInhibitors of Histone Deacetylase as New Anticancer Agents
Jung, M. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372058 · Cited by 213
Maeda, T., Towatari, M., Kosugi, H., & Saito, H. (2000) · Blood · doi:10.1182/blood.v96.12.3847 · Cited by 207 · cited 1×
“cgi?l=3383">ICAM1 , and type I and II interferons, to potentially augment immune-cell recognition and activatio”
BackgroundTranslocations of the RARα gene in acute promyelocytic leukemia
Zelent, A., Guidez, F., Melnick, A., Waxman, S., & Licht, J. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204766 · Cited by 207
Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., & Quaglia, M. P. L. (1999) · PubMed · Cited by 203
Carducci, M. A., Gilbert, J., Bowling, M. K., Noe, D. A., Eisenberger, M. A., Sinibaldi, V. J., Zabelina, Y., Chen, T., Grochow, L. B., & Donehower, R. C. (2001) · PubMed · Cited by 202
Activation of gene expression by small molecule transcription factors
Mapp, A. K., Ansari, A. Z., Ptashne, M., & Dervan, P. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.3930 · Cited by 184 · cited 1×
“Chimeric proteins that contain HAT or HDAC recruitment domains fused to hairpin polyamide”
BackgroundThe emerging role of class II histone deacetylases
Fischle, W., Kiermer, V., Dequiedt, F., & Verdin, E. (2001) · Biochemistry and Cell Biology · doi:10.1139/bcb-79-3-337 · Cited by 181 · cited 1×
“In APL, chromosomal translocations produce fusion proteins that contain RARα and PML (promyelocyticleukaemia protein) [t(15;17)], and RARα and PLZF (promyelocytic zinc finger) [t(11;17)].”
BackgroundAML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML
Licht, J. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204593 · Cited by 180
Transcriptional regulation in acute promyelocytic leukemia
Lin, R. J., Sternsdorf, T., Tini, M., & Evans, R. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204853 · Cited by 179
Transcription therapy for cancer
Pandolfi, P. P. (2001) · Oncogene · doi:10.1038/sj.onc.1204299 · Cited by 179
Mishra, N., Brown, D. R., Olorenshaw, I. M., & Kammer, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051507098 · Cited by 178
Chromatin remodeling and Rb activity
Harbour, J. W., & Dean, D. C. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00152-6 · Cited by 176
The ins and outs of nucleosome assembly
Mello, J. A., & Almouzni, G. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00170-2 · Cited by 172 · cited 1×
“Alternatively, it might reflect the cellular response to incorrect packaging of newly synthesized DNA, which requires the transient acetylation and deacetylation of histones during replicatio”
BackgroundCoffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 171
Komatsu, Y., Tomizaki, K., Tsukamoto, M., Kato, T., Nishino, N., Sato, S., Yamori, T., Tsuruo, T., Furumai, R., Yoshida, M., et al. (2001) · PubMed · Cited by 163
Weiser, T. S., Guo, Z. S., Ohnmacht, G. A., Parkhurst, M. L., Tong-On, P., Marincola, F. M., Fischette, M. R., Yu, X., Chen, G. A., Hong, J. A., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200103000-00010 · Cited by 162
Mechanisms for ATP-dependent chromatin remodelling
Flaus, A., & Owen-Hughes, T. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00172-6 · Cited by 162
Telomerase activation by histone deacetylase inhibitor in normal cells
Takakura, M. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.14.3006 · Cited by 154
Chromatin remodeling in development and differentiation
Müller, C., & Leutz, A. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00175-1 · Cited by 151 · cited 1×
“Cell development and differentiation is governed by the hierarchical order of sequential gene activation, which is controlled at the level of chromatin structur”
BackgroundKosugi, H., Towatari, M., Hatano, S., Kitamura, K., Kiyoi, H., Kinoshita, T., Tanimoto, M., Murate, T., Kawashima, K., Saito, H., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401508 · Cited by 150
Modifying chromatin and concepts of cancer
Jacobson, S. J., & Pillus, L. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80027-6 · Cited by 144 · cited 1×
“In cancer, the molecular processes that lead to inappropriate expression of genes due to altered chromatin structure are now being identified, and aberrant acetylation of histone tails has been strongly linked to carcinogenesi”
BackgroundSternson, S. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2001) · Organic Letters · doi:10.1021/ol016915f · Cited by 141
Liang, J., Prouty, L., Williams, B. J., Dayton, M. A., & Blanchard, K. L. (1998) · Blood · doi:10.1182/blood.v92.6.2118 · Cited by 141
Up-Regulation of p21WAF1/CIP1 by Histone Deacetylase Inhibitors Reduces Their Cytotoxicity
Burgess, A. J., Pavey, S., Warrener, R., Hunter, L.-J. K., Piva, T. J., Musgrove, E. A., Saunders, N., Parsons, P. G., & Gabrielli, B. G. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12311-5 · Cited by 136
Uh, W., & Grossmann, A. (2000) · PubMed · Cited by 131
Bernhard, D., Ausserlechner, M. J., Tonko, M., Löffler, M., Hartmann, B. L., Csordas, A., & Kofler, R. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1991 · Cited by 130 · cited 1×
“In addition, overexpression of the cowpox virus serpin crmA (cytokine-response modifier protein) inhibits caspase-8 activation and CD95-induced apoptosis but does not affect apoptosis that is induced by SAHA or butyrat”
BackgroundCao, X. X., Mohuiddin, I., Ece, F., McConkey, D. J., & Smythe, W. R. (2001) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.25.5.4539 · Cited by 123 · cited 1×
“These data are supported by findings that HDAC-inhibitor-induced apoptosis is coincident with upregulation of pro-apoptotic BCL2 proteins and downregulation of anti-apoptotic BCL2 family member”
MethodSuzuki, T., Yokozaki, H., Kuniyasu, H., Hayashi, K., Naka, K., Ono, S., Ishikawa, T., Tahara, E., & Yasui, W. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001215)88:6<992::aid-ijc24>3.0.co;2-9 · Cited by 121 · cited 1×
“These data are supported by findings that HDAC-inhibitor-induced apoptosis is coincident with upregulation of pro-apoptotic BCL2 proteins and downregulation of anti-apoptotic BCL2 family member”
MethodRemiszewski, S. W., Sambucetti, L. C., Atadja, P., Bair, K. W., Cornell, W. D., Green, M. A., Howell, K. L., Jung, M., Kwon, P., Trogani, N., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm015568c · Cited by 113
Sensing of Ionizing Radiation-induced DNA Damage by ATM through Interaction with Histone Deacetylase
Kim, G. D., Choi, Y. H., Dimtchev, A., Jeong, S. J., Dritschilo, A., & Jung, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31127 · Cited by 110
Histone Deacetylase: A Target for Antiproliferative and Antiprotozoal Agents
Meinke, P., & Liberator, P. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373787 · Cited by 103
Amin, H. M., Saeed, S., & Alkan, S. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03123.x · Cited by 93 · cited 1×
“Other HDAC inhibitors have been reported to require caspases to induce death of their target cell”
BackgroundSodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells
Terao, Y., Nishida, J.-I., Horiuchi, S., Rong, F., Ueoka, Y., Matsuda, T., Kato, H., Furugen, Y., Yoshida, K., Kato, K., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1448 · Cited by 89 · cited 1×
“gov/cancer_information/cancer_type/cervical/">cervical carcinomas , although high millimolar concentrations are required for their antitumour effect”
BackgroundCancer cell sensitization to Fas-mediated apoptosis by sodium butyrate
Bonnotte, B., Favre, N., Reveneau, S., Micheau, O., Droin, N. M., Garrido, C., Fontana, A., Chauffert, B., Solary, É., & Martin, F. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400371 · Cited by 88
Rosato, R., Wang, Z., Gopalkrishnan, R., Fisher, P., & Grant, S. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.1.181 · Cited by 87
Greenberg, V. L., Williams, J. M., Cogswell, J. P., Mendenhall, M. D., & Zimmer, S. G. (2001) · Thyroid · doi:10.1089/10507250152039046 · Cited by 77
Trapani, J. A., Jans, P., Smyth, M. J., Froelich, C. J., Williams, E. A., Sutton, V. R., & Jans, D. A. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400373 · Cited by 75
Kihara-Negishi, F., Yamamoto, H., Suzuki, M., Yamada, T., Sakurai, T., Tamura, T., & Oikawa, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204756 · Cited by 69
Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression
Wang, R., Brunner, T., Zhang, L., & Shi, Y. (1998) · Oncogene · doi:10.1038/sj.onc.1202059 · Cited by 66 · cited 1×
“, and depsipeptide inhibits CD95L expression after T-cell activation and suppresses subsequent T-cell deat”
BackgroundBernhard, D., Skvortsov, S., Tinhofer, I., Hübl, H., Greil, R., Csordás, A., & Kofler, R. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400914 · Cited by 65
Shestakova, E., Bandu, M.-T., Doly, J., & Bonnefoy, E. (2001) · Journal of Virology · doi:10.1128/jvi.75.7.3444-3452.2001 · Cited by 58 · cited 1×
“cgi?l=3383">ICAM1 , and type I and II interferons, to potentially augment immune-cell recognition and activatio”
BackgroundTip60 and HDAC7 Interact with the Endothelin Receptor A and May Be Involved in Downstream Signaling
Lee, H.-J., Chun, M., & Kandror, K. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000909200 · Cited by 58 · cited 1×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundKosugi, H., Ito, M., Yamamoto, Y., Towatari, M., Ito, M., Ueda, R., Saito, H., & Naoe, T. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01126.x · Cited by 46 · cited 1×
“In addition, the combination of depsipeptide and RA prevents death of NOD/SCID mice that are injected with a human APL [t(15;17)] cell line expressing the PML–RARα fusion protein, whereas treatment with either agent alone has no effec”
BackgroundHiebert, S. W., Lutterbach, B. A., Durst, K. L., Wang, L., Linggi, B. E., Wu, S. W., Wood, L. D., Amann, J. M., King, D., & Hou, Y. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100302 · Cited by 30
Greenberg, V. L., Williams, J. M., Boghaert, E. R., Mendenhall, M. D., Ain, K. B., & Zimmer, S. G. (2001) · Thyroid · doi:10.1089/10507250150500621 · Cited by 21
(2001) · PubMed
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070
“, Johnstone, A.M., Lobley, G.E., Wallace, R.J., et al. (2011). High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health.”
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
“A large number of studies have demonstrated that various TNF receptor super family members and their ligands are transcriptionally activated following HDACi treatment (see Ref”
BackgroundSelf-citationHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
“A relatively wide range of structures have been identified that are able to inhibit the activity of class 1, class 2 and class 4 HDAC”
BackgroundDrug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
“…at UIC, as well as panels of diverse mechanistic and cell-based assays at RTI and BMS. Examples of mechanism-based assays include a proteasome inhibition assay (Almond and Cohen, 2002; Adams, 2004) and a histone deacetylase (HDAC) inhibition assay (Johnstone, 2002; Villar-Garea and Esteller, 2004).”
Method
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.